Foresee Pharmaceuticals Co Ltd

Foresee Pharmaceuticals maintains a high liquidity position with a current ratio of 3.44 and cash and equivalents of TWD 203.7 million, though its operating cash flow is negative at TWD -842.2 million. The company’s price-to-book ratio of 13.47 and price-to-tangible-book ratio of 13.47 suggest a premium valuation relative to its equity base. The company’s profitability is weak, with a net loss of TWD -883.2 million and a return on equity of -9.5%, significantly below the industry median for biotechnology firms. Gross profit of TWD 294.2 million represents 68% of revenue, but operating income is negative at TWD -862.3 million, indicating high R&D and operational costs. Foresee’s revenue is concentrated in its core pharmaceutical development and clinical trial services, with no disclosed geographic diversification in the financial snapshot. The company operates primarily in Taiwan, and its revenue is entirely attributed to this region. The company’s revenue growth is not evident in the latest period, with a reported revenue of TWD 431.3 million. Analysts have not provided forward-looking revenue estimates, and the company’s operating cash flow remains negative, suggesting limited near-term growth visibility. Risk factors include a negative net cash position after subtracting total debt and a high liquidity risk due to negative operating cash flow. The company’s diluted share count is unchanged from basic shares, indicating no near-term dilution pressure. Recent events include the continued development of FP-001 and FP-025, with no disclosed regulatory approvals or clinical trial milestones in the latest financial filing. The company’s 10-K Risk Factors section highlights ongoing R&D costs and clinical trial uncertainties.